XML 40 R21.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Disposition | 12 Months Ended
--- | ---
Sep. 30, 2017
Disposal Groups, Including Discontinued Operations and Collaborative Agreement [Abstract] |
Disposition | Disposition Blood Screening Business On December 14, 2016, the Company entered into a definitive agreement to sell the assets of its blood screening business to its long-time commercial partner, Grifols for a sales price of $1.85 billion in cash, subject to adjustment based on an estimated closing amount of inventory. The divestiture was completed on January 31, 2017, and the Company received $1.865 billion. The sale resulted in a gain of $899.7 million recorded in the second quarter of fiscal 2017 within operations in the Consolidated Statements of Income. As a result of this disposition and proceeds received, the Company recorded a tax obligation of $649.5 million, which was paid during fiscal 2017. Upon the closing of the transaction, the Company's existing collaboration agreement with Grifols terminated, and a new collaboration agreement was executed as part of this transaction pursuant to which the Company provides certain research and development services to Grifols. In addition, the Company agreed to provide transition services to Grifols over the next two to three years depending on the nature of the respective service, including the manufacture of inventory. The Company has also agreed to sell Panther instrumentation and certain supplies to Grifols as part of a long term supply agreement. In determining the accounting for the multiple elements of the overall arrangement, the Company allocated $13.1 million of the proceeds to these elements based on their estimated fair values. The Company determined this disposal does not qualify to be reported as a discontinued operation as the blood screening business was deemed not to be strategic to the Company and has not had and will not have a major effect on the Company's operations and financial results. Under the previous collaboration agreement, the Company performed research and development activities and manufacturing, while Grifols performed the commercial and distribution activities. The blood screening business was embedded within the Company's molecular diagnostics business, and the Company retains ownership and will continue to use the intellectual property for the underlying technology of its molecular diagnostics assays and instrumentation. Income from operations of the disposed business presented below represents the pretax profit of the business as it was operated prior to the date of disposition. The operating expenses include only those that were incurred directly by and were retained by the disposed business and are now incurred by Grifols. As noted above, the Company is performing a number of transition services and the financial impact from these services are not included in the amounts presented below and the Company is in effect serving as a contract manufacturer of assays for Grifols for a two to three year period. Income from operations of the disposed business for the years periods ended September 30, 2017 and September 24, 2016 was as follows:
| Twelve Months Ended
| September 30, 2017 | September 24, 2016
Income from operations | $ | 45.8 |  | $ | 99.1 |
Under the long term supply agreement and transition services agreement to manufacture assays, subsequent to disposing the blood screening business, the Company recognized $44.0 million of revenue in fiscal 2017. Prior Collaboration Agreement with Grifols Under its prior collaboration agreement with Grifols, the Company manufactured blood screening products, while Grifols was responsible for marketing, sales and service of those products, which Grifols sold under its trademarks. The Company was entitled to recover 50% of its manufacturing costs incurred in connection with the collaboration and received a percentage of the blood screening assay revenue generated under the collaboration. The Company’s share of revenue from assays it sold to Grifols was 50%. The Company recognized product revenue, and collaborative research and license revenue, which is included within services and other revenues, under the prior collaboration agreement. The Company recognized revenue of $96.5 million, $235.4 million and $253.1 million under this collaboration agreement in fiscal 2017, 2016, and 2015 respectively.

X
- Definition Disposal Groups, Including Discontinued Operations and Collaborative Agreement [Abstract] + References No definition available. + Details
Name: | holx_DisposalGroupsIncludingDiscontinuedOperationsandCollaborativeAgreementAbstract
Namespace Prefix: | holx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disposal Groups, Including Discontinued Operations and Collaborative Agreement, Disclosure [Text Block] + References No definition available. + Details
Name: | holx_DisposalGroupsIncludingDiscontinuedOperationsandCollaborativeAgreementDisclosureTextBlock
Namespace Prefix: | holx_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration